Alan vs Exscientia

Alan has a disclosed valuation of $1.4B, while Exscientia's valuation is not publicly available, making a direct size comparison difficult. Alan employs 500-1000 people.

Exscientia has raised more in total funding at $500M, compared to Alan's $220M — a gap of $280M.

Alan holds the higher Awaira Score at 83/100, compared to Exscientia's 72/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 11-point gap that reflects meaningful differences in scale or traction.

Alan was founded by Jean-Charles Samuelian in 2016. Exscientia was founded by Andrew Hopkins in 2012. Visit each company's profile on Awaira for a full founder biography.

Alan: Alan is an AI-powered health insurance platform that combines employer group health insurance products with a digital health companion application, using AI to personalise member health recommendations, streamline claims processing, and provide on-demand access to telehealth and mental health resources. The Paris company holds full insurance carrier status in France, Belgium, and Spain, operating as a licensed insurer rather than a distribution intermediary.\n\nThe company raised approximately $220 million including a Series D round from investors including Temasek, Coatue, and Index Ventures, reaching a valuation of approximately $1.4 billion. Alan reports over half a million members across its markets, covering employees at several thousand companies including Stripe, Spendesk, and Vinted, with strong growth in SME employer sales driven by its digital-first enrolment and claims experience. The Alan app provides members with health navigation, symptom checking, and AI-generated health content in addition to insurance card and claims management functionality.\n\nAlan competes in the European digital health insurance market against traditional mutuals including Malakoff Humanis and AG2R La Mondiale, as well as digital health insurers including Henner and Oscar Health in the US context. Its vertical integration as a licensed insurer combined with a technology platform differentiates it from insurtechs that distribute existing insurer products through digital channels, giving Alan full control over the member experience and claims economics. The company is considered one of the most significant French technology companies building in regulated financial services. Exscientia: Exscientia is an AI-driven drug design company that uses automated design-make-test-analyse cycles to generate drug candidates with the goal of reducing the time and cost of small molecule drug discovery. The Oxford-originated company builds generative chemistry models and automated laboratory robotics that together create a closed-loop system for molecular design, synthesis, and assay testing, producing candidates in months rather than the years required by conventional medicinal chemistry programmes.\n\nThe company went public on NASDAQ under the ticker EXAI, having raised over $500 million in combined public and private funding from investors including Bristol-Myers Squibb, Celgene, SoftBank, and GT Healthcare Capital Partners. Exscientia has clinical-stage programmes in oncology and neuropsychiatry and reports being the first company to advance AI-designed drug candidates into human clinical trials. The company has multiple pharma partnerships including agreements with Bristol-Myers Squibb, Sanofi, and Evotec that provide milestone and royalty revenue.\n\nExscientia competes in the AI drug design space against Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics, and Insilico Medicine. The company differentiates through its integrated automated laboratory approach, which combines computational design with physical synthesis and testing in a single workflow rather than treating AI design as a separate step before conventional chemistry. Its public market position and disclosed clinical programmes provide transparency benchmarks against which the broader AI drug discovery sector is measured by investors and pharmaceutical partners.

Exscientia was founded first in 2012, giving it 4 years of additional market experience. Alan was founded later in 2016. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Alan has approximately 500-1000 employees, while Exscientia has approximately 100-500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Alan and Exscientia are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.